Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) : vimarsana.com

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...

Related Keywords

Christina Tartaglia , John Quisel , Nasdaq , Disc Medicine Inc , Verge Scientific Communications , Exchange Commission , Patient Global Impression , Chief Executive , Erythropoietic Protoporphyria , X Linked Protoporphyria , Private Securities Litigation Reform Act , Annual Report ,